Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 14/20 | 0.63 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.63 |
| ▸ | LMNA | P02545 | 4/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.63 |
| ▸ | ESRRA | P11474 | 3/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.63 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.63 |
| ▸ | PGR | P06401 | 2/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | ESRRB | O95718 | 2/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.63 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.63 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2854638 | 1.00 | ESR1 (0.63) | ESR1ESR2LMNAHSD17B10ESRRA | |
| SCHEMBL8505904 | 1.00 | ESR1 (0.63) | ESR1ESR2LMNAHSD17B10ESRRA | |
| SCHEMBL806967 | 1.00 | ESR1 (0.63) | ESR1ESR2LMNAHSD17B10ESRRA | |
| SCHEMBL24103220 | 1.00 | ESR1 (0.63) | ESR1ESR2LMNAHSD17B10ESRRA | |
| SCHEMBL16485139 | 1.00 | ESR1 (0.63) | ESR1ESR2LMNAHSD17B10ESRRA | |
| SCHEMBL24103217 | 1.00 | ESR1 (0.63) | ESR1ESR2LMNAHSD17B10ESRRA | |
| SCHEMBL14569768 | 1.00 | ESR1 (0.63) | ESR1ESR2LMNAHSD17B10ESRRA | |
| SCHEMBL24583080 | 1.00 | ESR1 (0.63) | ESR1ESR2LMNAHSD17B10ESRRA | |
| SCHEMBL13301006 | 0.89 | ESR1 (0.50) | ESR1ESR2LMNAHSD17B10ESRRA | |
| SCHEMBL14540439 | 0.89 | ESR1 (0.65) | ESR1ESR2LMNAHSD17B10ESRRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240151679-A1 | ELECTROCHEMICAL SENSOR FOR PHENOLIC ANALYTES | EYE3CONCEPTS INC. (CA) | 2024-05-09 | — | — | US | disclosed |
| US-20100204497-A1 | Process For The Preparation of 7 alpha-Methylsteroids | N.V. ORGANON | 2010-08-12 | — | — | US | disclosed |
| US-7772218-B2 | Synthesis of anti-estrogenic and other therapeutic steroids from 21-hydroxy-19-norpregna-4-en-3-one | SRI INTERNATIONAL (US) | 2010-08-10 | — | — | US | disclosed |
| EP-1470151-B1 | PROCESS FOR THE PREPARATION OF 7-ALPHA-METHYLSTEROIDS | ORGANON NV (NL) | 2009-12-30 | — | — | EP | disclosed |
| US-20050090476-A1 | Process for the preparation of 7alpha-methylsteroids | MERCK SHARP & DOHME B.V. (NL) | 2005-04-28 | — | — | US | disclosed |
| US-6852710-B2 | 2-alkoxyestradiol analogs with antiproliferative and antimitotic activity | SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH (US) | 2005-02-08 | — | — | US | disclosed |
| US-20050009801-A1 | Synthesis of anti-estrogenic and other therapeutic steroids from 21-hydroxy-19-norpregna-4-en-3-one | PETERS RICHARD H (US) | 2005-01-13 | — | — | US | disclosed |
| US-6784170-B2 | TREATMENT OF PROSTATE DISORDERS SUCH AS PROSTATIC CANCER | SRI INTERNATIONAL | 2004-08-31 | — | — | US | disclosed |
| US-20030229061-A1 | Novel 2-alkoxyestradiol analogs with antiproliferative and antimitotic activity | SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH | 2003-12-11 | — | — | US | disclosed |
| US-6593321-B2 | Compounds to inhibit undesired cell proliferation and tumor growth. Additionally, methods are disclosed of treating diseases associated with undesired angiogenesis and undesired proliferation, and methods of treating infectious disease | SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH | 2003-07-15 | — | — | US | disclosed |
| US-20030096799-A1 | Novel 2-alkoxyestradiol analogs with antiproliferative and antimitotic activity | SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH | 2003-05-22 | — | — | US | disclosed |
| WO-2002100877-A1 | NOVEL 2-ALKOXYESTRADIOL ANALOGS WITH ANTIPROLIFERATIVE AND ANTIMITOTIC ACTIVITY | SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH (US) | 2002-12-19 | — | — | WO | disclosed |
| WO-2001058919-A9 | SYNTHESIS OF ANTI-ESTROGENIC AND OTHER THERAPEUTIC STEROIDS FROM 21-HYDROXY-19-NORPREGNA-4-EN-3-ONE | STANFORD RES INST INT (US) | 2002-01-03 | — | — | WO | disclosed |
| US-20010039269-A1 | Synthesis of anti-estrogenic and other therapeutic steroids from 21-hydroxy-19-norpregna-4-en-3-one | SRI INTERNATIONAL | 2001-11-08 | — | — | US | disclosed |
| WO-2001058919-A2 | SYNTHESIS OF ANTI-ESTROGENIC AND OTHER THERAPEUTIC STEROIDS FROM 21-HYDROXY-19-NORPREGNA-4-EN-3-ONE | SRI INTERNATIONAL (US) | 2001-08-16 | — | — | WO | disclosed |
| EP-0719276-B1 | ORALLY ACTIVE DERIVATIVES OF 1,3,5(10)-ESTRATRIENE | US HEALTH (US) | 1997-11-26 | — | — | EP | disclosed |
| US-5554603-A | 11,17-DINITRATES; USE TO ACHIEVE ESTROGENIC EFFECT IN FEMALE MAMMALS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-09-10 | — | — | US | disclosed |
| EP-0719276-A1 | ORALLY ACTIVE DERIVATIVES OF 1,3,5(10)-ESTRATRIENE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-07-03 | — | — | EP | disclosed |
| WO-1995007925-A1 | ORALLY ACTIVE DERIVATIVES OF 1,3,5(10)-ESTRATRIENE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039269-A1 | Synthesis of anti-estrogenic and other therapeutic steroids from 21-hydroxy-19-norpregna-4-en-3-one | NR5A1, HSD17B11, CYP17A1 | ESR1 14/4885ESR2 15/4885LMNA 3199/4885 |
| US-20050090476-A1 | Process for the preparation of 7alpha-methylsteroids | CYP17A1, CYP21A2, HSD17B7 | ESR1 670/4885ESR2 505/4885LMNA 2326/4885 |
| US-20050009801-A1 | Synthesis of anti-estrogenic and other therapeutic steroids from 21-hydroxy-19-norpregna-4-en-3-one | CYP17A1, NR5A1, HSD17B11 | ESR1 13/4885ESR2 20/4885LMNA 3276/4885 |
| US-20030096799-A1 | Novel 2-alkoxyestradiol analogs with antiproliferative and antimitotic activity | HSD17B11, CDC42, TUBB1 | ESR1 200/4885ESR2 36/4885LMNA 2996/4885 |
| US-20100204497-A1 | Process For The Preparation of 7 alpha-Methylsteroids | CYP17A1, CYP21A2, HSD17B7 | ESR1 665/4885ESR2 465/4885LMNA 2421/4885 |
| US-20030229061-A1 | Novel 2-alkoxyestradiol analogs with antiproliferative and antimitotic activity | HSD17B11, CDC42, TUBB1 | ESR1 200/4885ESR2 36/4885LMNA 2996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.